User discusses using trichosol as a vehicle for hair loss treatments like finasteride and minoxidil. They ask about others' experiences and the stability of the solutions.
Charts show how long Finasteride and Dutasteride stay in the blood, explaining why 0.5 mg Finasteride is less effective than 1 mg. Dutasteride accumulates over time, leading to gradual results compared to the immediate effects of Finasteride.
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
A user stopped oral finasteride after 7 years due to decreased libido and switched to topical finasteride and minoxidil. Others shared similar experiences and discussed alternatives like dutasteride and topical treatments.
A user is considering using a 0.025% topical finasteride solution with DMSO to enhance absorption but is unsure about its effectiveness and safety. Other users express concerns about DMSO's properties and potential effects on the scalp.
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
The conversation discusses creating a customized minoxidil formulation with tretinoin, azelaic acid, and caffeine, but there are concerns about foam stabilization due to acidity. The user seeks advice on the best formulation for effective results.
The conversation discusses the use of ethanol and propylene glycol (PG) in topical solutions for hair loss treatments, specifically Minoxidil. The user dislikes the texture of PG and questions the ideal ratio and necessity of PG in these solutions.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
The conversation is about creating a DIY topical finasteride solution using ethyl alcohol and propylene glycol. A user suggests using a compounding pharmacy instead.
The user experienced a decrease in libido after long-term use of Finasteride and wonders if it's related to the medication. Responses suggest that hormonal changes and libido fluctuations are normal and may not be solely due to Finasteride.
RU58841 mixed with Minoxidil seems less effective over time, so the user plans to switch to a PG and Ethanol dilution for better results. They also consider using rosemary oil with Minoxidil to enhance RU58841 absorption.
PP405 is progressing rapidly through trials, with mixed opinions on its potential effectiveness. Current treatments like minoxidil and finasteride are still widely discussed, with some users reporting positive results from new formulations.
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
A user experienced increased testosterone and estradiol levels after starting finasteride/dutasteride and is asking if these levels will return to normal over time. The conversation focuses on whether these changes are temporary.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
The user is looking for a PG-free solvent in the UK or EU to make their own pyrilutamide solution for hair loss and is currently using finasteride, considering minoxidil. They hope pyrilutamide will help stabilize their hair loss.
Topical finasteride concentrations and application amounts are debated, with concerns that mainstream solutions may use arbitrary concentrations. A 0.25% solution with a specific application method is suggested as more appropriate than higher concentrations.
The conversation is about making a topical finasteride solution by dissolving crushed finasteride tablets in an alcohol-based hair treatment. Ingredients of the hair treatment include alcohol, water, and various plant extracts and preservatives.
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
The user has been using liposomal topical finasteride since late 2022, progressively increasing the dose, but DHT serum levels remain largely unchanged. Despite using finasteride, minoxidil, microneedling, and ketoconazole, hair condition has neither improved nor worsened.
The conversation discusses the best vehicle for topical dutasteride, comparing Trichosol, Transcutol, and a gel version. It also mentions using Transcutol with ethanol to enhance transdermal delivery of Bimatoprost.
A user started using homemade topical finasteride with PG-free liquid minoxidil for hair loss. They noticed the solution became milky with floaters and asked if it needed filtering.
The user added melatonin to their 5% minoxidil solution for hair growth, using a concentration of 0.0033%, which equates to roughly 2mg for a 60ml bottle. They later reported no significant difference and planned to continue the treatment for a few more months before potentially stopping to observe any changes in shedding.
The user realized they didn't shake their HappyHead Topical Fin + Min before use, leading to inconsistent application of Finasteride due to sediment at the bottle's bottom. They advise others to shake their topical hair loss treatments before use.
The conversation discusses the ineffectiveness of tablet forms of dutasteride for hair loss due to poor absorption compared to soft gel capsules. It suggests switching to FDA-approved soft gel capsules for better results, as tablets may not adequately suppress DHT levels.
User shares 8-month progress on oral finasteride and minoxidil, noting initial success followed by a second shed. They seek advice on drug resistance and pill efficacy, with responses suggesting to push through the shed and consider the impact of cycling off minoxidil.